Treasuries End Lower Across Curve

Treasuries End Lower Across Curve

Treasuries prices ended lower across the curve Thursday, curves were mixed with 5Y and longer flatter vs longer dated maturities. The USD enjoyed a big rally with the DXY hitting the highest since late July as equities charged ahead on the pro-reflation trade, posting new all time highs. Meanwhile, the GBP was down nearly 1% due to uncertainty over the future of Prime Minister Theresa May while the EUR was […]

Read More ˃
Tech Stocks Close Gap With Financial Sector for Market Lead

Tech Stocks Close Gap With Financial Sector for Market Lead

Technology stocks were ending mostly higher, helping to carry the broader U.S. markets to gains, with shares of tech companies in the S&P 500 rising more than 0.9% in recent trade. In company news, NeoPhotonics (NPTN) fell to a 30-month low on Thursday, sinking to its lowest price since March 2015 at $4.93 a share, after the maker of digital optical receivers and switches said it was beginning an aggressive […]

Read More ˃
Health Care Stocks Pare Nearly All of Thursday Losses

Health Care Stocks Pare Nearly All of Thursday Losses

Most health care stocks largely sat out the advance for stocks, with the NYSE Health Care Index sinking almost 0.1% while shares of health care companies in the S&P 500 were down less than 0.1% as a group. In company news, Valeritas Holdings (VLRX) stumbled Thursday after late Wednesday disclosing plans to sell up to 3.35 million shares of its common stock by Aspire Capital Partners, which late last month […]

Read More ˃
Alliqua BioMedical Effects 1-for-10 Reverse Stock Split

Alliqua BioMedical Effects 1-for-10 Reverse Stock Split

Alliqua BioMedical (ALQA) said Thursday it will effect a reverse stock split of its issued and outstanding common stock at an exchange ratio of 1-for-10, after the close of business on Oct. 5. As a result of the reverse stock split, there will be approximately 4.9 million shares of common stock outstanding. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in […]

Read More ˃
New Jersey Files Four-Count Lawsuit Against Insys on Opioid Drug – Stock Down 1.7%

New Jersey Files Four-Count Lawsuit Against Insys on Opioid Drug – Stock Down 1.7%

New Jersey has filed a four-count lawsuit against Insys Therapeutics (INSY) charging that it engaged in a greed-driven campaign of consumer fraud and submission of false claims to health insurers to increase the market share for its powerful opioid-fentanyl drug Subsys, Attorney General Christopher Porrino said on Thursday. Insys shares were down 1.5% in late trade. The suit charged that, despite Subsys’ only having Food and Drug Administration (FDA) approval […]

Read More ˃